Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, Pal S, Bhatia R, Raubitschek A, Yu H, Kortylewski M.

Blood. 2013 Feb 21;121(8):1304-15. doi: 10.1182/blood-2012-07-442590. Epub 2013 Jan 3.

2.

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, Forman S, Bhatia R, Kuo YH, Kortylewski M.

Blood. 2014 Jan 2;123(1):15-25. doi: 10.1182/blood-2013-07-517987. Epub 2013 Oct 29.

3.

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, Cai Q, Swiderski P, Kuo YH, Forman S, Marcucci G, Kortylewski M.

Blood. 2016 Mar 31;127(13):1687-700. doi: 10.1182/blood-2015-08-665604. Epub 2016 Jan 21.

4.

Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.

Nechaev S, Gao C, Moreira D, Swiderski P, Jozwiak A, Kowolik CM, Zhou J, Armstrong B, Raubitschek A, Rossi JJ, Kortylewski M.

J Control Release. 2013 Sep 28;170(3):307-15. doi: 10.1016/j.jconrel.2013.06.007. Epub 2013 Jun 15.

5.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H.

Nat Biotechnol. 2009 Oct;27(10):925-32. doi: 10.1038/nbt.1564. Epub 2009 Sep 13.

6.

TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.

Moreira D, Zhang Q, Hossain DM, Nechaev S, Li H, Kowolik CM, D'Apuzzo M, Forman S, Jones J, Pal SK, Kortylewski M.

Oncotarget. 2015 Jul 10;6(19):17302-13.

7.

TLR9-Targeted SiRNA Delivery In Vivo.

Hossain DM, Moreira D, Zhang Q, Nechaev S, Swiderski P, Kortylewski M.

Methods Mol Biol. 2016;1364:183-96. doi: 10.1007/978-1-4939-3112-5_15.

8.

TLR9 is critical for glioma stem cell maintenance and targeting.

Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H.

Cancer Res. 2014 Sep 15;74(18):5218-28. doi: 10.1158/0008-5472.CAN-14-1151. Epub 2014 Jul 21.

9.

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M.

Cancer Res. 2010 Dec 1;70(23):9816-26. doi: 10.1158/0008-5472.CAN-10-1251. Epub 2010 Oct 8.

10.

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2013 Jan 3;121(1):136-47. doi: 10.1182/blood-2012-01-407742. Epub 2012 Nov 19.

11.

TLR9 signaling promotes tumor progression of human lung cancer cell in vivo.

Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H, Wen Z.

Pathol Oncol Res. 2009 Dec;15(4):623-30. doi: 10.1007/s12253-009-9162-0. Epub 2009 Mar 25.

PMID:
19319670
12.

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M.

Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12.

13.

Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W.

Blood. 2010 Jun 17;115(24):5041-52. doi: 10.1182/blood-2009-03-213363. Epub 2010 Mar 25.

14.

Down-regulation of TLR9 expression affects the maturation and function of murine bone marrow-derived dendritic cells induced by CpG.

Ma L, Zhao G, Hua C, Li X, Zhao X, Sun L, Hou Y.

Cell Mol Immunol. 2009 Jun;6(3):199-205. doi: 10.1038/cmi.2009.27.

15.

G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells.

Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H.

J Biol Chem. 2013 May 10;288(19):13842-9. doi: 10.1074/jbc.M113.450049. Epub 2013 Apr 2.

16.

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.

Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K.

Biomaterials. 2014 Jul;35(21):5491-504. doi: 10.1016/j.biomaterials.2014.03.039. Epub 2014 Apr 8.

17.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2. Erratum in: J Clin Invest. 2015 Jun;125(6):2547. Swiderski, Piotr [Added].

18.

Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Kortylewski M, Moreira D.

Cancer Immunol Immunother. 2017 Feb 18. doi: 10.1007/s00262-017-1966-2. [Epub ahead of print] Review.

PMID:
28214929
19.

Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis.

Huang X, Barrett RP, McClellan SA, Hazlett LD.

Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4209-16.

PMID:
16249500
20.

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS.

Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005.

Supplemental Content

Support Center